Brendan Wang
Director
Brendan J. Wang supports Back Bay projects across a wide range of therapeutic areas, from rare and orphan disease indications to novel oncology and immuno-oncology therapies. He frequently supports clients on commercial opportunity assessments for novel therapeutics and prioritization of indications and assets for further development.
Mr. Wang’s recent project work at Back Bay has focused on supporting clients with novel gene-editing platforms to differentiate their technologies in highly competitive and fast-moving markets. He frequently advises clients on pricing and market access considerations at early stages of development, blending Back Bay’s focus on early-stage clients and technologies with his prior work experience for commercial-stage products and companies.
Prior to Back Bay Life Science Advisors, Mr. Wang advised pharma, biotech, and medical device clients on a variety of strategic business needs across pricing, market access, and commercial strategy spanning several geographies, including the US, Canada, EU-5, Japan, and others.
Mr. Wang holds an A.B. in Chemistry with Honors from Dartmouth College, where his thesis focused on analyzing the electronic properties of semiconducting zinc sulfide nanoclusters using computational chemistry techniques.
Select industry insights by Mr. Wang:
New Drug Pricing and Market Access [Podcast]
An Analysis Of The Gene Therapy Viral Vector Landscape
Cell & Gene: The Next Decade In Gene Therapy Innovation, Six Critical Questions (And Answers)
Life Science Leader: First In Line: FDA Vs. EMA Biopharma Approval Times
Insights Magazine: Cell & Gene Therapy in Canada: Leading Companies and the Commercial Opportunity